BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...also includes a biosimilar version of Soliris eculizumab...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...involved in the original launch of Soliris eculizumab...
...price, but noted that the use of Soliris...
BioCentury | Feb 3, 2021
Finance

argenx raises $1B as it readies to challenge Soliris

...of the front-running myasthenia gravis agents poised to challenge Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Soliris...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...of three drugs approved for NMOSD in the past three years, alongside C5 inhibitor Soliris eculizumab...
BioCentury | Dec 15, 2020
Deals

In $39B deal, AZ looks to grow rare disease business while Alexion’s investors gain value recognition

...years, its flagship complement inhibition franchise of Soliris eculizumab...
...expand its revenue base beyond C5 inhibitor Soliris...
...adipsin) – Complement factor D Stephen Hansen Soliris, eculizumab (5G1.1) Alexion...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...Phase III study, the C3 inhibitor led to significant improvements in hemoglobin levels compared with Soliris eculizumab...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...in hereditary angioedema patients. The other two are IV-delivered anti-C5 mAbs from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): Soliris eculizumab...
...ravulizumab-cwvz, both of which are approved to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH). Soliris...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...Co. Ltd., including rights in China to biosimilars to Lucentis ranibizumab (SB11), Eylea aflibercept, Soliris eculizumab...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...the study’s primary endpoint.It would enter a market with one approved therapy, C5 inhibitor Soliris eculizumab...
...NASDAQ:ARGX), for which that biotech intends to submit a BLA by year-end (see “Data For Soliris...
...as the company intends to test a monthly dosage as well as a subcutaneous version. Soliris...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...in myasthenia gravis (see “Argenx Data put Myasthenia Gravis Therapy a Step Closer to Challenging Soliris”...
Items per page:
1 - 10 of 549